Topics
Diffuse midline glioma | Treatment | Immunotherapy | Vaccines
Home > Publications > Topics > Diffuse midline glioma > Treatment > Immunotherapy > Vaccines
*Boschert
T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne
K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K,
Platten M, Lindner JM, Green EW.
H3K27M
neoepitope vaccination in diffuse midline glioma induces B and T
cell responses across diverse HLA loci of a recovered patient.
Sci
Adv.
2024 Feb 2;10(5):eadi9091. doi:
10.1126/sciadv.adi9091. PMID:
38306431. Case
report. ˍ
RELATED
ARTICLE
Vincent
CA, Remeseiro S.
The
immune response behind peptide vaccination in diffuse midline
glioma.
Mol
Oncol.
2024 Jun 16. doi:
10.1002/1878-0261.13686. PMID:
38880657. Comment. ˍ
Hashii Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K,
Takahara-Matsubara M, Goto M, Yanagisawa T, Kikuta A, Kawamoto H,
Hashimoto N, Oka Y, Sugiyama H, Hara J.
Phase
1/2 study of a WT1 peptide-dosing emulsion in pediatric patients
with recurrent/refractory diffuse intrinsic pontine glioma,
glioblastoma, or anaplastic astrocytoma.
Eur
J Cancer. 2026 May 19;242:116808. doi:
10.1016/j.ejca.2026.116808. PMID:
42176363. Trial
registration ID: NCT02750891˰
ˍ